The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ERIC 2022 | Overcoming resistance to CAR-T therapy in CLL with ibrutinib & venetoclax
Marco Ruella, MD, University of Pennsylvania, Philadelphia, PA, discusses strategies to overcome resistance to CAR-T therapy in chronic lymphocytic leukemia (CLL), commenting on the addition of ibrutinib and venetoclax to CAR-T therapy, and highlighting the use of gene editing techniques to engineer improved CAR-T constructs. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
